Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentosan Polysulfate Sodium in Knee Osteoarthritis Pain
2022-500228-31-00Phase 3Withdrawn
- Sponsor
- Paradigm Biopharmaceuticals
- Start
- Jun 2022
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in knee osteoarthritis (OA) comparing Pentosan polysulfate sodium with Placebo (2 arms). Primary endpoints: Change from baseline at Day 56 in knee pain and Change from baseline at Day 56 in function. Planned start Jun 2022; status: withdrawn.
02
Drugs
pentosan polysulfate sodium
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2022-500228-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500228-31-00.